Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
something is really going on here...... should push nearer 4p today , looks good for a Friday RNS or Monday. Possibly some good news on the Lung cancer trials and asthma trials, maybe a couple of contracts
you are on a winner - congrats mate
http://citywire.co.uk/wealth-manager/shrewdie-why-medical-minnow-akers-could-be-a-gem/a472877
US$3.2 Million Purchase Order - Revelar Free Radical Assay Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, has secured a purchase order totaling US$3,242,200 to manufacture and supply Revelar breath tubes to Pulse Health, LLC under the Company's Supply Agreement, as announced on 11 April 2011. This is the first purchase order under the Supply Agreement and manufacturing will commence immediately, from ABI's New Jersey facility, with the majority of this order expected to be fulfilled during 2011. Revelar provides the first accurate measurement system that both detects and measures aldehydes in exhaled breath. Aldehydes are known to be indicators of free radical activity that are thought to negatively impact or damage healthy cells throughout the human body. External factors, such as diet, activity, stress, chemicals and pollutants cause the body to produce excess free radicals that damage healthy cells. Studies show this may lead to heart disease, cancer and rapid aging. Millions of people in the developed world are consuming antioxidant supplements to counteract this process but neither patients, nor healthcare practitioners, have previously been able to accurately and efficiently determine whether a regime is working to improve patient health. The Revelar Assay, which consists of an electronic analyser and disposable breath tubes, instantly measures a patient's baseline aldehyde level and provides a numerical score, providing the first rapid, non-invasive way to measure the effectiveness of an antioxidant regimen and other interventions. Pulse Health, LLC, based in Portland, Oregon, is supplying The Revelar Assay to healthcare practitioners - particularly chiropractic centres - and health supplement producers and distributors initially in the USA and throughout the EU and then worldwide, where the sale of antioxidant products represents a multi-billion dollar annual market. Thomas A. Nicolette, President and Chief Executive of ABI, commented, "Pulse Health has identified a significant opportunity to provide an easy-to-use assay that empowers patients and healthcare practitioners with the knowledge to evaluate the effectiveness of a regime and adapt accordingly. We are extremely excited to be supplying this truly progressive test using ABI's proprietary breath condensate collection technology."
Outlook H12011 has been a momentum-building business cycle for both current and emerging products derived from ABI's platform technologies. The Company's commitment to growth and operational efficiency has translated into a 53% increase in Revenues and a 64% improvement in Gross Profit Margin as compared to the same period last year. That performance, paired with the successful equity raise in February of this year, has resulted in a 67% increase in the Company's cash position over the last 12 months. With this firm debt-free foundation, ABI is confident that its distribution partnerships and direct selling efforts will generate incremental revenues through the second half of the year and into 2012.
911=News on the way...
Thanks Riddler
still below my breakeven but in the right direction.
Will do.Entry before the 15th looks sensible..
I did,looking very positive indeed. Still can't thank you enough fella,last time:A BIG FAT THANK YOU..
...and there it is.
Morning,did you see the 3 holding rns over @ vpha,any thoughts? Sorry to be off topic gl all
yes. still cant buy without negotiated trade. always a good sign... and sell price is over the midway point at 2.78
will it get number 1?
up 16%
looks very good. from iii board I expect you are referring to the RNS 18 April 2011 - ABI Starts Clinical Trials for Breath Asthma Check Rapid Assay "Akers Biosciences is pleased to announce that clinical trials have commenced for the Company's Breath Asthma Check rapid assay in Clearwater, FL, USA. The trials have been designed to provide the clinical information to be included in a submission for regulatory approvals for the test in the USA and EU, which ABI intends to submit towards the end of Q3 2011". McMather over on the ADFVN board commented yesterday "Apparently, now submitted - trials said to have gone well." Also from that board the link http://www.bizjournals.com/philadelphia/news/2011/11/17/new-jersey-oks-60m-in-tax-losscredit.html is good news for the companies finances Also good to see that the share price has moved up a bit again today - this one from azzi on ADFVN "Yes stock is hard to get at any volume, never got my 100k last week placed another order today and was offered even less than last week! Oh I could have paid 3p of course!..Actually that could turn out to be a bargain."
looking good, will we be getting some news?
3p seems very close now.
would be nice to see the 3p mark today.
trials due anytime. plus further contracts should be announced etc
Looking very promising,being offered 2.41 now...
We did have a chat recently on AAT,ref. some irritating people..
That £8k was mine.Still can't believe my luck! Put the order in,it went to NT and 10 minutes later..well chuffed..thanks again! Done no research(not as much as you anyway),just read your posts,you should charge commission..LOL
Following your tip got a substantial amount last thing Wednesday @2.10 without any problems,must have been pure luck..